LU91681I2 - "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" - Google Patents

"Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"

Info

Publication number: LU91681I2
Authority: LU; Luxembourg
Prior art keywords: revolade; eltrombopag; solvate; hydrate; optionally
Prior art date: 2000-05-25

Application number

LU91681C

Other languages

English (en)

Other versions

LU91681I9 (fr

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2010-04-21

Publication date

2010-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91681(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-21 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2010-06-21 Publication of LU91681I2 publication Critical patent/LU91681I2/fr

2019-01-03 Publication of LU91681I9 publication Critical patent/LU91681I9/fr

Links

XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 title 2
229960001069 eltrombopag Drugs 0.000 title 2
150000003839 salts Chemical class 0.000 title 1
239000012453 solvate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hard Magnetic Materials (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Information Transfer Systems (AREA)
Vehicle Body Suspensions (AREA)

LU91681C 2000-05-25 2010-04-21 "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" LU91681I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20708400P	2000-05-25	2000-05-25
US22892900P	2000-08-30	2000-08-30
PCT/US2001/016863 WO2001089457A2 (fr)	2000-05-25	2001-05-24	Mimiques de thrombopoietine

Publications (2)

Publication Number	Publication Date
LU91681I2 true LU91681I2 (fr)	2010-06-21
LU91681I9 LU91681I9 (fr)	2019-01-03

Family

ID=26901947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91681C LU91681I2 (fr)	2000-05-25	2010-04-21	"Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"

Country Status (30)

Country	Link
US (9)	US7160870B2 (fr)
EP (3)	EP1889838B1 (fr)
JP (2)	JP3813875B2 (fr)
KR (2)	KR100798568B1 (fr)
CN (4)	CN101342169A (fr)
AR (2)	AR030696A1 (fr)
AT (2)	ATE445606T1 (fr)
AU (2)	AU2001274938C1 (fr)
BE (1)	BE2010C018I2 (fr)
BR (1)	BRPI0111116B8 (fr)
CA (1)	CA2411468C (fr)
CY (4)	CY2010012I2 (fr)
CZ (1)	CZ303176B6 (fr)
DE (4)	DE60130760T2 (fr)
DK (3)	DK1889838T3 (fr)
ES (3)	ES2294000T3 (fr)
FR (1)	FR10C0034I2 (fr)
HK (1)	HK1056114A1 (fr)
HU (3)	HU230487B1 (fr)
IL (5)	IL152988A0 (fr)
LU (1)	LU91681I2 (fr)
MX (1)	MXPA02011621A (fr)
MY (1)	MY136707A (fr)
NO (3)	NO324246B1 (fr)
NZ (2)	NZ533308A (fr)
PL (2)	PL218617B1 (fr)
PT (3)	PT1864981E (fr)
SI (3)	SI1864981T1 (fr)
TW (1)	TWI305207B (fr)
WO (1)	WO2001089457A2 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1607401A1 (fr) *	2000-03-08	2005-12-21	Metabasis Therapeutics, Inc.	Nouveaux inhibiteurs de la fructose-1,6-bisphosphatase, à base d'aryle
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US20110212054A1 (en) *	2000-05-25	2011-09-01	Glaxosmithkline Llc.	Thrombopoietin mimetics
EP1370252A4 (fr) *	2001-03-01	2006-04-05	Smithkline Beecham Corp	Mimetiques de la thrombopoietine
US7659409B2 (en)	2002-03-19	2010-02-09	Mitsubishi Chemical Corporation	3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
MY142390A (en) *	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7414040B2 (en) *	2002-06-06	2008-08-19	Smithkline Beecham Corporation	Thrombopoietin mimetics
US7851503B2 (en)	2002-08-14	2010-12-14	Nissan Chemical Industries, Ltd.	Thrombopoetin receptor activator and process for producing the same
TWI324593B (en)	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
EP1622609A4 (fr) *	2003-04-29	2008-09-03	Smithkline Beecham Corp	Procedes de traitement de maladies/lesions degeneratives
US20100004302A1 (en) *	2003-04-29	2010-01-07	Connie Erickson-Miller	Methods for Treating Degenerative Diseases/Injuries
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US7753958B2 (en) *	2003-08-05	2010-07-13	Gordon Charles R	Expandable intervertebral implant
SE0302486D0 (sv) *	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (fr)	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Composes modulant l'activite de la thrombopoietine et methodes associees
EP1805142A4 (fr) *	2004-09-23	2009-06-10	Reddy Us Therapeutics Inc	Composes a base de pyridine, leur procede de preparation et compositions les contenant
DE602005024599D1 (de) *	2004-10-25	2010-12-16	Ligand Pharm Inc	Verbindungen modulierende thrombopoietinaktivität und verfahren
WO2006062240A1 (fr)	2004-12-08	2006-06-15	Nissan Chemical Industries, Ltd.	Composes heterocycliques a substitution 3-ethylidenehydrazino utilises en tant qu’activateurs du recepteur de la thrombopoietine
KR101215207B1 (ko)	2004-12-14	2012-12-26	닛산 가가쿠 고교 가부시키 가이샤	아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
TW200716580A (en)	2005-06-08	2007-05-01	Smithkline Beecham Corp	(5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
JP5071375B2 (ja)	2005-07-15	2012-11-14	日産化学工業株式会社	チオフェン化合物及びトロンボポエチンレセプター活性化剤
JP5104752B2 (ja)	2005-07-20	2012-12-19	日産化学工業株式会社	ピラゾール化合物及びトロンボポエチンレセプター活性化剤
WO2007044982A2 (fr) *	2005-10-13	2007-04-19	Smithkline Beecham Corporation	Méthodes pour conserver l'efficacité de plaquettes pendant le stockage
US8026368B2 (en)	2005-11-07	2011-09-27	Nissan Chemical Industries, Ltd.	Hydrazide compounds and thrombopoietin receptor activators
US8093251B2 (en)	2006-06-07	2012-01-10	Nissan Chemical Industries, Ltd.	Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
JP2010511631A (ja) *	2006-12-01	2010-04-15	ステイテジックス・インコーポレイテッド	トロンボポエチン擬態物
US20110160130A1 (en) *	2007-02-16	2011-06-30	Connie Erickson-Miller	Cancer treatment method
US20110129550A1 (en)	2007-02-16	2011-06-02	Connie Erickson-Miller	Cancer treatment method
UY30915A1 (es) *	2007-02-16	2008-09-02	Smithkline Beecham Corp	Método de tratamiento de canceres
US20100160644A1 (en) *	2007-04-24	2010-06-24	Jerome Francis Hayes	Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
KR101530402B1 (ko) *	2007-10-09	2015-06-19	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (ｔｐｏｒａ)
CN101481352A (zh) *	2008-01-10	2009-07-15	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US8236838B2 (en)	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
EP2278879B1 (fr)	2008-04-21	2016-06-15	PATH Drug Solutions	Composés, compositions et traitements comprenant des dérivés d'oxydiazoles
WO2009151862A1 (fr) *	2008-05-15	2009-12-17	Smithkline Beecham Corporation	Procédé de traitement
WO2010045310A1 (fr) *	2008-10-16	2010-04-22	Glaxosmithkline Llc	Méthode de traitement de la thrombocytopénie
PE20100362A1 (es)	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
US7956048B2 (en)	2009-04-01	2011-06-07	Pliva Hrvatska D.O.O.	Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
EP2427053A4 (fr) *	2009-05-07	2012-12-05	Glaxosmithkline Llc	Procédé de traitement de la thrombocytopénie
US8476249B2 (en)	2009-05-07	2013-07-02	Glaxosmithkline Llc	Method of treating thrombocytopenia
US8680150B2 (en) *	2009-05-28	2014-03-25	Ligand Pharmaceuticals, Inc.	Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP2434894B1 (fr) *	2009-05-29	2016-08-31	Novartis AG	Procédés d'administration de composés agonistes de la thrombopoïétine
CN101921232A (zh)	2009-06-11	2010-12-22	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
KR101830203B1 (ko)	2009-12-01	2018-02-20	바스프 에스이	폴리우레탄을 주성분으로 하는 인발성형 수지 시스템
CN101805291A (zh) *	2010-04-26	2010-08-18	西北大学	1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
CA2808908A1 (fr)	2010-09-01	2012-03-08	Novartis Ag	Association d'inhibiteurs de hdac et de medicaments contre la thrombopenie
WO2012102937A2 (fr)	2011-01-25	2012-08-02	Irm Llc	Composés qui développent des cellules souches hématopoïétiques
WO2012121958A2 (fr) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Association
WO2012121957A1 (fr) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Association
US20120309796A1 (en)	2011-06-06	2012-12-06	Fariborz Firooznia	Benzocycloheptene acetic acids
WO2013006806A1 (fr) *	2011-07-06	2013-01-10	Cellerant Therapeutics, Inc.	Cellules progénitrices mégacaryocytaires pour la production de plaquettes
SG2014012926A (en) *	2011-08-30	2014-06-27	Chdi Foundation Inc	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755955A4 (fr)	2011-09-13	2015-08-19	Glenmark Generics Ltd	Procédé de préparation de composés substitués de l'acide 3'-hydrazino-biphényl-3-carboxylique
WO2013049605A1 (fr)	2011-09-28	2013-04-04	Assia Chemical Industries Ltd.	Procédés de préparation d'un intermédiaire dans la synthèse de l'eltrombopag
CA3173988A1 (fr)	2011-10-11	2013-04-18	Dana-Farber Cancer Institute, Inc.	Pyrazol-3-ones qui activent le bax pro-apoptotique
US9492430B2 (en)	2011-11-14	2016-11-15	Ligand Pharmaceuticals, Incorporated	Methods and compositions associated with the granulocyte colony-stimulating factor receptor
WO2013086436A1 (fr)	2011-12-08	2013-06-13	Fred Hutchinson Cancer Research Center	Compositions et procédés pour la génération améliorée de cellules souches/progénitrices hématopoïétiques
SI2807165T1 (sl)	2012-01-27	2019-08-30	Universite De Montreal	Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
CN103360317B (zh) *	2012-04-11	2016-12-14	齐鲁制药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) *	2012-05-22	2015-08-27	国立大学法人旭川医科大学	ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) *	2012-08-13	2014-02-13	University Of Rochester	Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2014150252A1 (fr)	2013-03-15	2014-09-25	Ligand Pharmaceuticals Incorporated	Méthodes de traitement associées au récepteur du facteur de stimulation des colonies de granulocytes
EP2799425A1 (fr)	2013-04-29	2014-11-05	Esteve Química, S.A.	Procédé de préparation d'un agoniste du récepteur de la thrombopoïétine
US9770437B2 (en)	2013-09-02	2017-09-26	Hetero Research Foundation	Compositions of eltrombopag
ITMI20131782A1 (it) *	2013-10-25	2015-04-26	Dipharma Francis Srl	Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) *	2013-11-12	2015-05-20	上海医药工业研究院	3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种爱曲伯帕的合成方法
WO2015111085A2 (fr)	2014-01-27	2015-07-30	Cadila Healthcare Limited	Procédés de préparation d'eltrombopag et sels pharmaceutiquement acceptables, solvates et intermédiaires de celui-ci
CN103819406B (zh) *	2014-03-17	2015-04-08	苏州明锐医药科技有限公司	艾曲波帕的制备方法
CA2946446C (fr)	2014-04-22	2020-11-03	Universite De Montreal	Composes de pyrido-pyrrolo-pyrimidine et de pyrido-indole, compositions pharmaceutiques contenant ces composes et leur utilisation dans l'expansion de cellules souches hematopoietiques et/ou de cellules progenitrices hematopoietiques
CN105085276A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	艾曲波帕中间体及其制备方法和应用
CN105085287A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
MX372995B (es)	2014-07-17	2020-04-13	Chdi Foundation Inc	Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
US10336706B2 (en)	2014-09-05	2019-07-02	Hetero Research Foundation	Crystalline form of Eltrombopag free acid
WO2016055935A1 (fr)	2014-10-06	2016-04-14	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine
SG11201703407UA (en)	2014-10-31	2017-05-30	Nissan Chemical Ind Ltd	Ligand-binding fiber and cell culture substrate using said fiber
CN104829593B (zh) *	2015-03-26	2017-08-25	苏州福来兹检测科技有限公司	一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (fr)	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Nouveau sel d'eltrombopag et préparation de celui-ci
EP3445571B1 (fr)	2016-04-21	2020-02-26	Basf Se	Procédé de pultrusion et produit a base de polyurethane obtenu
JP7104636B2 (ja)	2016-06-27	2022-07-21	ザジェネラルホスピタルコーポレーションドゥーイングビジネスアズマサチューセッツジェネラルホスピタル	ミトコンドリア生物の活性化による血小板産生刺激
WO2018162519A1 (fr)	2017-03-09	2018-09-13	Basf Se	Formulations de polyuréthane pour la production d'éléments composites
CN107021928B (zh) *	2017-04-01	2022-11-18	常州制药厂有限公司	艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (fr)	2017-04-26	2019-08-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition de comprimé pharmaceutique comprenant eltrombopag olamine
EP3692021A1 (fr)	2017-10-06	2020-08-12	Assia Chemical Industries Ltd	Formes à l'état solide d'eltrombopag choline
EP3409272B1 (fr)	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
CN110467531B (zh) *	2018-05-09	2022-04-19	新发药业有限公司	一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
EP3802651A4 (fr) *	2018-06-01	2022-05-04	Aurobindo Pharma Limited	Procédé amélioré pour la préparation d'eltrombopag olamine et de ses intermédiaires
EP3604284B1 (fr)	2018-08-02	2020-11-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Forme cristalline d du sel de monoéthanolamine d'eltrombopag
EP3604285B1 (fr)	2018-08-02	2020-06-17	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Forme cristalline d1 hautement stable du sel de monoéthanolamine d'eltrombopag
US20220071961A1 (en) *	2019-01-08	2022-03-10	Jiangsu Hengrui Medicine Co., Ltd.	Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative
EP3994126A1 (fr)	2019-07-04	2022-05-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procédé de préparation d'intermédiaires clés pour la synthèse d'eltrombopag ou d'un sel de celui-ci
JP7083793B2 (ja) *	2019-09-10	2022-06-13	Ｊｆｅケミカル株式会社	パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
WO2021055820A1 (fr)	2019-09-20	2021-03-25	Novartis Ag	Acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et sa formulation de sels
WO2021078076A1 (fr) *	2019-10-21	2021-04-29	广东东阳光药业有限公司	Nouvelle forme cristalline d'eltrombopag acétylé et son procédé de préparation
CN114341113A (zh) *	2019-10-21	2022-04-12	广东东阳光药业有限公司	乙酰化艾曲波帕的新晶型及其制备方法
WO2021110942A1 (fr)	2019-12-06	2021-06-10	Synthon B.V.	Composition pharmaceutique comprenant de l'eltrombopag bis(monoéthanolamine)
CA3160779A1 (fr)	2019-12-06	2021-06-10	Synthon B.V.	Composition pharmaceutique comprenant de l'eltrombopag bis(monoethanolamine)
TR202014694A1 (tr)	2020-09-16	2022-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (fr)	2021-03-25	2022-09-29	Novartis Ag	Formulation d'acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidène]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et de ses sels
CN113336704B (zh) *	2021-06-11	2022-10-11	上海大学	丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) *	2021-12-02	2022-05-17	天津力生制药股份有限公司	一种艾曲波帕的制备方法
EP4436554A1 (fr)	2021-12-15	2024-10-02	Galenicum Health SLU	Compositions pharmaceutiques comprenant de l'eltrombopag
CN116354885A (zh) *	2021-12-27	2023-06-30	苏州特瑞药业股份有限公司	一种艾曲波帕新晶型及其制备方法
WO2025140275A1 (fr) *	2023-12-25	2025-07-03	江苏恒瑞医药股份有限公司	Composé phosphate de dérivé azoïque de pyrazoline substitué ou sel pharmaceutiquement acceptable de celui-ci

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (fr)
US851444A (en)	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) *	1954-10-26	1957-10-15	Ciba Ltd	Azo-dyestuffs
DE1046220B (de) *	1956-04-21	1958-12-11	Bayer Ag	Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en)	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en)	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en)	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es)	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) *	1984-02-10	1986-12-05	Sandoz Sa	Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi)	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en)	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
WO1993017681A1 (fr)	1992-03-02	1993-09-16	Abbott Laboratories	Antagonistes du recepteur d'angiotensine ii
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (fr)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Sels de pigments
EP0661170B1 (fr)	1993-12-28	1998-09-02	Dai Nippon Printing Co., Ltd.	Feuille pour transfert thermique
GB2285446B (en) *	1994-01-03	1999-07-28	Genentech Inc	Thrombopoietin
WO1995021920A1 (fr)	1994-02-14	1995-08-17	Zymogenetics, Inc.	Proteine hematopoietique, produits et methodes pour la preparer
US5482546A (en)	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en)	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en)	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
CN1966520B (zh)	1995-06-07	2012-07-11	葛兰素集团有限公司	结合血小板生成素受体的肽和化合物
US5622818A (en)	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en)	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en)	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en)	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
WO1999011262A1 (fr)	1997-09-02	1999-03-11	Roche Diagnostics Gmbh	Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US20010016568A1 (en)	1997-10-31	2001-08-23	Juan I. Luengo	Novel metal complexes
DE19851389A1 (de)	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) *	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
US6750342B1 (en) *	1999-05-19	2004-06-15	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
KR20020069183A (ko)	1999-07-26	2002-08-29	시오노기세이야쿠가부시키가이샤	트롬보포이에틴 작동성을 나타내는 의약 조성물
AU770564B2 (en) *	1999-09-10	2004-02-26	Smithkline Beecham Corporation	Thrombopoietin mimetics
AU771460B2 (en) *	1999-09-24	2004-03-25	Smithkline Beecham Corporation	Thrombopoietin mimetics
JP2003513965A (ja)	1999-11-05	2003-04-15	スミスクライン・ビーチャム・コーポレイション	セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
EP1104674A1 (fr)	1999-11-10	2001-06-06	Curacyte AG	Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
AR030273A1 (es) *	2000-03-10	2003-08-20	Smithkline Beecham Corp	Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
US6214813B1 (en) *	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6436915B1 (en) *	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US6642265B1 (en) *	2000-09-08	2003-11-04	Smithkline Beecham Corporation	Thrombopoietin mimetics
JP2004520302A (ja)	2000-12-19	2004-07-08	スミスクライン・ビーチャム・コーポレイション	トロンボポエチン模倣物
JP2004532614A (ja)	2000-12-21	2004-10-28	スミスクライン・ビーチャム・コーポレイション	金属キレート化アゴニストによる細胞膜受容体の活性化の調節
MXPA03006510A (es)	2001-01-26	2003-10-15	Shionogi & Co	Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
WO2002059099A1 (fr)	2001-01-26	2002-08-01	Shionogi & Co., Ltd.	Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
EP1370252A4 (fr)	2001-03-01	2006-04-05	Smithkline Beecham Corp	Mimetiques de la thrombopoietine
JP3927001B2 (ja)	2001-06-15	2007-06-06	三菱化学株式会社	色素セット、インクセット並びに記録方法
US6560161B1 (en) *	2001-08-30	2003-05-06	Micron Technology, Inc.	Synchronous flash memory command sequence
JP2005519878A (ja)	2001-11-30	2005-07-07	キネテクファーマシューティカルズ，インコーポレーテッド	ヒドラゾノピラゾール誘導体および治療剤としてのその使用
AU2003213673A1 (en)	2002-03-01	2003-09-16	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
MY142390A (en)	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7414040B2 (en) *	2002-06-06	2008-08-19	Smithkline Beecham Corporation	Thrombopoietin mimetics
TWI324593B (en) *	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
US20060084682A1 (en)	2002-12-13	2006-04-20	Heerding Dirk A	Thrombopoietin mimetics
EP1622609A4 (fr) *	2003-04-29	2008-09-03	Smithkline Beecham Corp	Procedes de traitement de maladies/lesions degeneratives
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (fr) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Composes modulant l'activite de la thrombopoietine et methodes associees
DE602005024599D1 (de) *	2004-10-25	2010-12-16	Ligand Pharm Inc	Verbindungen modulierende thrombopoietinaktivität und verfahren
WO2007044982A2 (fr) *	2005-10-13	2007-04-19	Smithkline Beecham Corporation	Méthodes pour conserver l'efficacité de plaquettes pendant le stockage
JP2010511631A (ja) *	2006-12-01	2010-04-15	ステイテジックス・インコーポレイテッド	トロンボポエチン擬態物

2000
- 2000-06-03 CY CY2010012C patent/CY2010012I2/el unknown
2001
- 2001-05-23 TW TW090112317A patent/TWI305207B/zh not_active IP Right Cessation
- 2001-05-23 AR ARP010102468A patent/AR030696A1/es active IP Right Grant
- 2001-05-23 MY MYPI20012430A patent/MY136707A/en unknown
- 2001-05-24 HU HU0800710A patent/HU230487B1/hu not_active IP Right Cessation
- 2001-05-24 DE DE60130760T patent/DE60130760T2/de not_active Expired - Lifetime
- 2001-05-24 DK DK07112106.5T patent/DK1889838T3/da active
- 2001-05-24 CN CNA2008101297607A patent/CN101342169A/zh active Pending
- 2001-05-24 ES ES01941599T patent/ES2294000T3/es not_active Expired - Lifetime
- 2001-05-24 AU AU2001274938A patent/AU2001274938C1/en not_active Expired
- 2001-05-24 EP EP07112106A patent/EP1889838B1/fr not_active Expired - Lifetime
- 2001-05-24 HK HK03106754.0A patent/HK1056114A1/zh unknown
- 2001-05-24 PL PL393259A patent/PL218617B1/pl unknown
- 2001-05-24 KR KR1020027015869A patent/KR100798568B1/ko not_active Expired - Lifetime
- 2001-05-24 PL PL359270A patent/PL216528B1/pl unknown
- 2001-05-24 CN CN200810129758XA patent/CN101343250B/zh not_active Expired - Fee Related
- 2001-05-24 DE DE60139354T patent/DE60139354D1/de not_active Expired - Lifetime
- 2001-05-24 PT PT07112105T patent/PT1864981E/pt unknown
- 2001-05-24 SI SI200130938T patent/SI1864981T1/sl unknown
- 2001-05-24 CA CA002411468A patent/CA2411468C/fr not_active Expired - Lifetime
- 2001-05-24 DE DE60140224T patent/DE60140224D1/de not_active Expired - Lifetime
- 2001-05-24 EP EP07112105A patent/EP1864981B8/fr not_active Expired - Lifetime
- 2001-05-24 CN CN2008101297594A patent/CN101343251B/zh not_active Expired - Fee Related
- 2001-05-24 SI SI200130790T patent/SI1294378T1/sl unknown
- 2001-05-24 ES ES07112106T patent/ES2334843T3/es not_active Expired - Lifetime
- 2001-05-24 CN CNB018133401A patent/CN100423721C/zh not_active Expired - Lifetime
- 2001-05-24 ES ES07112105T patent/ES2328179T3/es not_active Expired - Lifetime
- 2001-05-24 JP JP2001585703A patent/JP3813875B2/ja not_active Expired - Lifetime
- 2001-05-24 BR BRPI0111116A patent/BRPI0111116B8/pt not_active IP Right Cessation
- 2001-05-24 AT AT07112106T patent/ATE445606T1/de active
- 2001-05-24 WO PCT/US2001/016863 patent/WO2001089457A2/fr not_active Ceased
- 2001-05-24 PT PT07112106T patent/PT1889838E/pt unknown
- 2001-05-24 DK DK01941599T patent/DK1294378T3/da active
- 2001-05-24 SI SI200130955T patent/SI1889838T1/sl unknown
- 2001-05-24 NZ NZ533308A patent/NZ533308A/en not_active IP Right Cessation
- 2001-05-24 US US10/296,688 patent/US7160870B2/en not_active Expired - Lifetime
- 2001-05-24 HU HU0302257A patent/HU227476B1/hu active Protection Beyond IP Right Term
- 2001-05-24 DE DE122010000037C patent/DE122010000037I1/de active Pending
- 2001-05-24 HU HU0800310A patent/HU230387B1/hu not_active IP Right Cessation
- 2001-05-24 DK DK07112105T patent/DK1864981T3/da active
- 2001-05-24 AU AU7493801A patent/AU7493801A/xx active Pending
- 2001-05-24 KR KR1020077018036A patent/KR100847172B1/ko not_active Expired - Fee Related
- 2001-05-24 NZ NZ522474A patent/NZ522474A/en not_active IP Right Cessation
- 2001-05-24 CZ CZ20023852A patent/CZ303176B6/cs not_active IP Right Cessation
- 2001-05-24 EP EP01941599A patent/EP1294378B1/fr not_active Expired - Lifetime
- 2001-05-24 PT PT01941599T patent/PT1294378E/pt unknown
- 2001-05-24 AT AT01941599T patent/ATE374772T1/de active
- 2001-05-24 IL IL15298801A patent/IL152988A0/xx active IP Right Grant
- 2001-05-24 MX MXPA02011621A patent/MXPA02011621A/es active IP Right Grant
2002
- 2002-11-20 IL IL152988A patent/IL152988A/en active Protection Beyond IP Right Term
- 2002-11-20 NO NO20025566A patent/NO324246B1/no active Protection Beyond IP Right Term
2005
- 2005-12-07 JP JP2005353686A patent/JP4546919B2/ja not_active Expired - Fee Related
2006
- 2006-11-09 US US11/558,071 patent/US7335649B2/en not_active Expired - Fee Related
2007
- 2007-01-05 US US11/620,260 patent/US7332481B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,688 patent/US7439342B2/en not_active Expired - Fee Related
- 2007-01-08 US US11/650,838 patent/US7452874B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,651 patent/US7473686B2/en not_active Expired - Lifetime
- 2007-12-13 CY CY20071101583T patent/CY1107087T1/el unknown
2008
- 2008-05-02 AR ARP080101867A patent/AR066036A2/es active IP Right Grant
- 2008-06-18 US US12/141,422 patent/US7648971B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,379 patent/US7674887B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,397 patent/US7790704B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193618A patent/IL193618A0/en not_active IP Right Cessation
- 2008-08-21 IL IL193619A patent/IL193619A0/en unknown
- 2008-08-21 IL IL193617A patent/IL193617A/en not_active IP Right Cessation
2009
- 2009-08-13 CY CY20091100873T patent/CY1109435T1/el unknown
2010
- 2010-01-11 CY CY20101100027T patent/CY1109730T1/el unknown
- 2010-04-13 BE BE2010C018C patent/BE2010C018I2/fr unknown
- 2010-04-21 LU LU91681C patent/LU91681I2/fr unknown
- 2010-06-18 FR FR10C0034C patent/FR10C0034I2/fr active Active
- 2010-08-19 NO NO2010017C patent/NO2010017I2/no unknown
2020
- 2020-11-19 NO NO2020040C patent/NO2020040I1/no unknown

Also Published As

Publication number	Publication date
HK1056114A1 (zh)	2004-02-06
IL193617A0 (en)	2009-02-11
DE60130760D1 (de)	2007-11-15
US20070129338A1 (en)	2007-06-07
DK1889838T3 (da)	2010-02-08
CY1109730T1 (el)	2014-09-10
CN101343250B (zh)	2011-09-21
IL152988A0 (en)	2003-06-24
US7439342B2 (en)	2008-10-21
WO2001089457A2 (fr)	2001-11-29
CY2010012I1 (el)	2012-01-25
US7335649B2 (en)	2008-02-26
PT1294378E (pt)	2008-01-09
CN101343251A (zh)	2009-01-14
HU0800310D0 (en)	2008-07-28
HUP0302257A2 (hu)	2003-10-28
NZ533308A (en)	2005-10-28
CN101342169A (zh)	2009-01-14
NO2020040I1 (no)	2020-11-19
ES2334843T3 (es)	2010-03-16
DE122010000037I1 (de)	2011-01-27
NO2010017I1 (no)	2010-09-20
US7648971B2 (en)	2010-01-19
PL218617B1 (pl)	2015-01-30
EP1889838B1 (fr)	2009-10-14
EP1864981B1 (fr)	2009-07-22
DK1864981T3 (da)	2009-09-07
US20040019190A1 (en)	2004-01-29
BRPI0111116B8 (pt)	2021-05-25
BR0111116B1 (pt)	2013-10-08
HU227476B1 (en)	2011-07-28
SI1889838T1 (sl)	2010-02-26
SI1294378T1 (sl)	2008-02-29
US20090155203A1 (en)	2009-06-18
JP3813875B2 (ja)	2006-08-23
EP1294378B1 (fr)	2007-10-03
MXPA02011621A (es)	2004-05-17
DE60130760T2 (de)	2008-07-17
CN1444477A (zh)	2003-09-24
AU7493801A (en)	2001-12-03
AU2001274938B2 (en)	2006-01-19
JP4546919B2 (ja)	2010-09-22
ATE445606T1 (de)	2009-10-15
NO20025566D0 (no)	2002-11-20
US20080214640A1 (en)	2008-09-04
BR0111116A (pt)	2003-04-08
BE2010C018I2 (fr)	2020-08-20
CN101343251B (zh)	2011-11-09
FR10C0034I1 (fr)	2010-06-08
DK1294378T3 (da)	2008-01-28
ES2294000T3 (es)	2008-04-01
KR100798568B1 (ko)	2008-01-28
ATE374772T1 (de)	2007-10-15
IL152988A (en)	2009-02-11
EP1294378A2 (fr)	2003-03-26
HK1113057A1 (en)	2008-09-19
NO2010017I2 (no)	2012-06-11
IL193619A0 (en)	2009-02-11
US7160870B2 (en)	2007-01-09
US7473686B2 (en)	2009-01-06
JP2006137764A (ja)	2006-06-01
HK1055561A1 (en)	2004-01-16
EP1294378A4 (fr)	2004-01-28
CN100423721C (zh)	2008-10-08
TWI305207B (en)	2009-01-11
NZ522474A (en)	2004-10-29
EP1864981A1 (fr)	2007-12-12
PL216528B1 (pl)	2014-04-30
EP1864981B8 (fr)	2009-11-11
ES2328179T3 (es)	2009-11-10
CY1109435T1 (el)	2014-08-13
AR030696A1 (es)	2003-09-03
PT1864981E (pt)	2009-08-31
US7674887B2 (en)	2010-03-09
CZ303176B6 (cs)	2012-05-16
HU230487B1 (hu)	2016-08-29
CN101343250A (zh)	2009-01-14
HUP0800710A2 (hu)	2003-10-28
DE60139354D1 (de)	2009-09-03
KR100847172B1 (ko)	2008-07-17
NO324246B1 (no)	2007-09-17
US20090176973A1 (en)	2009-07-09
IL193617A (en)	2013-06-27
CA2411468A1 (fr)	2001-11-29
US7332481B2 (en)	2008-02-19
HU0800710D0 (en)	2009-01-28
US7452874B2 (en)	2008-11-18
CA2411468C (fr)	2008-04-15
AR066036A2 (es)	2009-07-22
FR10C0034I2 (fr)	2011-04-29
CZ20023852A3 (cs)	2003-05-14
NO20025566L (no)	2003-01-22
DE60140224D1 (de)	2009-11-26
HK1117825A1 (en)	2009-01-23
AU2001274938C1 (en)	2006-09-28
PL393259A1 (pl)	2011-07-04
SI1864981T1 (sl)	2009-12-31
WO2001089457A3 (fr)	2002-03-07
KR20030060773A (ko)	2003-07-16
JP2003534257A (ja)	2003-11-18
LU91681I9 (fr)	2019-01-03
HUP0302257A3 (en)	2007-03-28
US7790704B2 (en)	2010-09-07
US20090176746A1 (en)	2009-07-09
CY1107087T1 (el)	2012-01-25
EP1889838A1 (fr)	2008-02-20
US20080090787A1 (en)	2008-04-17
HU230387B1 (hu)	2016-03-29
US20080090996A1 (en)	2008-04-17
KR20070087255A (ko)	2007-08-27
CY2010012I2 (el)	2020-05-29
PT1889838E (pt)	2010-01-19
US20070179192A1 (en)	2007-08-02
PL359270A1 (en)	2004-08-23
IL193618A0 (en)	2009-02-11
MY136707A (en)	2008-11-28

Publication	Publication Date	Title
LU92428I2 (fr)	2014-06-10	Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
NO2024019I1 (no)	2024-04-29	Lenvatinib eller et farmasøytisk akseptabelt salt derav eller et hydrat derav
LU92407I2 (fr)	2014-05-19	Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU91442I2 (fr)	2008-07-21	"Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU88842I2 (fr)	1997-01-27	Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU91372I2 (fr)	2007-12-24	Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU92939I2 (fr)	2016-03-07	Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable
LU91306I2 (fr)	2007-03-19	Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU91650I2 (fr)	2010-04-19	Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU88809I2 (fr)	1997-01-03	Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU92699I2 (fr)	2015-06-24	Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
LU90468I2 (fr)	2000-01-03	Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU93029I2 (fr)	2016-06-14	Alafenamide tenofovir ou un sel ou solvat de celui-ci, en particulier le fumarate d'alafenamide tenofovir
LU93066I2 (fr)	2016-07-11	Combinaison de a) olodatérol, isomèrers optiques individuels de celui-ci, melanges d'énantionmères indiviou de recémates, leurs sels d'addition d'acide avec des acides pharmaceutiquement acceptables, éventuellement sous forme de solvates et/ou hycrates, et b.) un sel de tiotropium ; en particulier une combinaison de a) olodatérol et sis sels d'addition d'acide avec des acides pharmaceutiquement acceptables et b.) du bromure de tiotropium, éventuellement sous forme de solvate et/ou hydrate , plus particulièrement une combinaison de a) hadrochlorure d'olodatérol et b.) de bromure de tiotropium, éventuellement sous forme de monohydrate
LU91027I2 (fr)	2004-04-28	Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable
NO2013003I1 (no)	2013-03-04	Boceprevir eller enantiomerer, stereoisomerer, rotamerer, tautomerer eller recemater av forbindelsen, eller farmasøytisk akseptable salter eller solvater av forbindelsen
LU91710I2 (fr)	2010-09-21	Pazopanib, facultativement sous forme d'un sel ou d'un solvate pharmaceutiquement acceptable de celui-ci
DE60135607D1 (de)	2008-10-16	Ung eines unterirdischen gebiets unter gleichzeitien
LU90593I2 (fr)	2000-08-07	Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
DZ3358A1 (fr)	2001-11-29	Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
AU2690402A (en)	2002-06-11	Tilt-up concrete form brace
PL354169A1 (en)	2003-12-29	Pharmaceutically active sulfonamide derivatives
LU91181I2 (fr)	2005-09-06	Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
AU4562000A (en)	2000-11-21	4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents
FR2792200B3 (fr)	2001-06-08	Substitut du tabac sous forme d'un comprime ou d'une pastille a sucer